The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer

Future Oncol. 2018 Feb;14(3):191-194. doi: 10.2217/fon-2017-0124. Epub 2018 Jan 16.

Authors

Rafael Santana-Davila¹, Laura Qm Chow¹

Affiliation

¹ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.

PMID: 29334785
DOI: 10.2217/fon-2017-0124

No abstract available

Keywords: NSCLC; chemo-immunotherapy; first-line; immune checkpoint inhibitors; immunotherapy; lung cancer; treatment naive.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / therapy*
Clinical Trials as Topic
Combined Modality Therapy
Humans
Immunomodulation / drug effects
Immunotherapy* / adverse effects
Immunotherapy* / methods
Lung Neoplasms / immunology
Lung Neoplasms / mortality
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Molecular Targeted Therapy
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor